This company listing is no longer active
Sensyne Health Valuation
Is DSH undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
5/6Valuation Score 5/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of DSH when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: DSH (€0.01) is trading below our estimate of fair value (€2.19)
Significantly Below Fair Value: DSH is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for DSH?
Other financial metrics that can be useful for relative valuation.
What is DSH's n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | UK£582.63k |
Key Statistics | |
---|---|
Enterprise Value/Revenue | n/a |
Enterprise Value/EBITDA | n/a |
PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does DSH's PS Ratio compare to its peers?
Company | Forward PS | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 2.7x | ||
IS8 ifa systems | 0.8x | n/a | €7.3m |
CHG CHAPTERS Group | 6.7x | 27.7% | €379.5m |
AJ91 DocCheck | 0.8x | n/a | €46.7m |
M3V MeVis Medical Solutions | 2.5x | n/a | €43.0m |
DSH Sensyne Health | 0.07x | 63.7% | €582.6k |
Price-To-Sales vs Peers: DSH is good value based on its Price-To-Sales Ratio (0.1x) compared to the peer average (2.8x).
Price to Earnings Ratio vs Industry
How does DSH's PE Ratio compare vs other companies in the European Healthcare Services Industry?
Price-To-Sales vs Industry: DSH is good value based on its Price-To-Sales Ratio (0.1x) compared to the German Healthcare Services industry average (2.8x)
Price to Sales Ratio vs Fair Ratio
What is DSH's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PS Ratio | 0.07x |
Fair PS Ratio | 11.8x |
Price-To-Sales vs Fair Ratio: DSH is good value based on its Price-To-Sales Ratio (0.1x) compared to the estimated Fair Price-To-Sales Ratio (11.8x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.